Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III
TerminatedPhase 4NCT00194597
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Viagra is a potent 5-PDE inhibitor that causes vasodilation in the penis and, therefore, erection in men with erectile dysfunction. Our hypothesis is that Viagra may improve the symptoms of men with Chronic Pelvic Pain Syndrome based on the following assumptions: Chronic Pelvic Pelvic Syndrome and Interstitial Cystitis involve poorly understood central and peripheral pain sensitization such as are seen in Chronic Sympathetic Dystrophy, also called Chronic Regional Pain Syndrome. This pain may be caused by constricted blood vessels resulting from past stress, injury or trauma Viagra will dilate sympathetically constricted vessels and improve pelvic blood flow in the same manner it does in men with erectile dysfunction. Since men with Chronic Pelvic Pain Syndrome often complain of sexual dysfunction; improving sexual function and, therefore, quality of life may improve overall well being and perception of pain.
Study details
- Official title
- Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III
- Conditions
- Interventions
- Drug: Viagra (sildenafil citrate)
- Sponsor
- University of Washington
- Collaborators
- Berger, Richard E., M.D.
- Start date
- 2004-07
- Sex
- Male
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Diagnosis of male Chronic Pelvic Pain Syndrome Type III * Age 18 - 65 * Pelvic pain duration of at least 3 months Exclusion Criteria: * Urinary tract infection within the last year * Sexually transmitted disease within 3 months * Antiviral therapy or antibiotics within the last 3 months * Currently taking any medications or recreational drugs containing nitrates 3A4 inhibitors such as erythromycin, ketoconazole, or itraconazole * Alpha-blocker therapy for treatment of high blood pressure or prostate problems * Suffered a heart attack, stroke or life-threatening arrhythmia within the last months * Cardiac failure or coronary artery disease causing unstable angina * Resting hypotension (BP\<90/50) or hypertension (BP\>170/110) * Patients with retinitis pigmentosa * Kidney, liver or blood problems (including sickle cell anemia or leukemia) * Allergy to sildenafil * Deformed penis, Peyronie's disease or ever having had an erection lasting more than 4 hours * Stomach ulcers or any types of bleeding problems * Use of any other medical treatments that cause erections: pills, medicines that are injected or inserted into the penis, implants or vacuum pumps * Back pain, unilateral testicular pain or rectal pain only * Post-surgical pain * Prostate biopsy or cystoscopy within 3 months * Pain from another source in the genital tract, such as kidney stones or neoplasm * History of prostate, bladder, renal or other urinary malignancies * History of intravesical Bacillus Calmette-Guerin (BCG) * Ulcerative colitis or Crohn's disease * Radiation therapy to pelvis * History of genitourinary tuberculosis * Any neurological abnormalities including spinal cord injury and stroke * Overtly psychotic or suicidal * Unable to understand the protocol In addition, subjects will be asked to refrain from having any new treatment for prostatitis during the study period, but will be allowed to remain on stable chronic therapy that they have been receiving for 3 or more months
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00194597